RituxiRel (rituximab biosimilar)
/ Reliance Life Sci, Torrent Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 06, 2016
The infectious profiles of biotherapeutic agents in an Algerian population
(WCO-IOF-ESCEO 2016)
- P=NA, N=107; “The products used were adalimumab (33.6 %) etanercept (29 %) rituximab (13 %) tocilizumab (13 %) and infliximab (11.2 %)…Infections events are more common in anti-TNFα treated patients than those on rituximab or tocilizumab.”
Clinical data • Biosimilar • Immunology
1 to 1
Of
1
Go to page
1